A daily preventive pill can be invaluable for people at risk for HIV. But some doctors don't know much about prescribing them. And billing headaches are common. Here's how to overcome those hurdles.

Findings showed 99.9% of participants in the lenacapavir group did not acquire HIV infection. Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil ...

Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...

Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. Biktarvy ...

An updated Canadian guideline on HIV prevention addresses the expanding range of medications available to reduce the risk of contracting the virus.

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Animal research is pointing toward a new way to prevent HIV infection: a refillable implant that continuously delivers antiretroviral medications for up to 20 months at a time. Antiretrovirals are the ...

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...

Gilead Sciences’ human immunodeficiency virus (HIV) single-tablet combination antiretroviral therapy (ART) has proven ...

Advances in treatment of HIV have improved the health and quality of life for so many. Advances in treatment of the disease have improved the health and quality of life for countless individuals.

HIV continues to be a significant public health concern in the United States, with an estimated 1.2 million people currently living with the virus and more than 30,000 new diagnoses in 2020 alone.